^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SPH 3348
i
Other names: SPH 3348
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shanghai Pharma
Drug class:
c-MET inhibitor
Related drugs:
2ms
SPH3348 Tablets in a Single-center, Randomized, Open-label, Single-dose, Two-period, Two-sequence Crossover Design Food Effect Study in Healthy Chinese Subjects (clinicaltrials.gov)
P1, N=16, Completed, West China Second University Hospital
New P1 trial
|
SPH 3348
4ms
Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors (clinicaltrials.gov)
P1, N=40, Completed, Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting --> Completed | N=231 --> 40
Trial completion • Enrollment change
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
SPH 3348
7ms
Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=231, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Jul 2024
Trial completion date • Trial primary completion date • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
SPH 3348
10ms
Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=231, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
Trial completion date • Trial primary completion date • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
SPH 3348
over1year
Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=231, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023
Trial completion date • Trial primary completion date • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase) • HGF (Hepatocyte growth factor)
|
SPH 3348
over1year
Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=231, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial primary completion date: Dec 2022 --> Jun 2023
Trial primary completion date • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase) • HGF (Hepatocyte growth factor)
|
SPH 3348
over2years
Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=231, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | N=36 --> 231 | Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Sep 2022 --> Dec 2022
Enrollment change • Trial completion date • Trial primary completion date
|
MET (MET proto-oncogene, receptor tyrosine kinase) • HGF (Hepatocyte growth factor)
|
SPH 3348
Share via
